Omega Healthcare Investors Earnings Call Transcripts
Fiscal Year 2025
-
Fourth quarter results showed strong revenue and earnings growth, driven by acquisitions and portfolio management, with AFFO and FAD both up over 8% year-over-year. The balance sheet was strengthened through significant debt reduction and new investments, while 2026 guidance projects continued growth and robust liquidity.
-
Q3 2025 saw strong revenue and earnings growth, driven by acquisitions and portfolio management, with raised AFFO guidance and robust liquidity. Major investments included a $222M SABR JV and a $93M OpCo stake, while portfolio coverage and occupancy reached multi-year highs.
-
Q2 2025 saw strong revenue and earnings growth, driven by acquisitions and portfolio management, with adjusted FFO of $0.77/share and FAD of $0.74/share. Guidance was raised, leverage hit a decade low, and major investments and legislative wins support a positive outlook.
-
Q1 2025 saw strong revenue and earnings growth, driven by new investments and improved operator performance, with leverage at a decade low. Guidance for 2025 AFFO was raised, and the investment pipeline remains robust, especially in the U.S. and U.K.
Fiscal Year 2024
-
Q4 2024 delivered strong revenue and FFO growth, with leverage at a decade low and robust capital deployment. 2025 guidance reflects share issuance dilution, stable operator performance, and a healthy acquisition pipeline, especially in the U.K.
-
Q3 results exceeded expectations with FAD at $0.70/share and revenue up 14% year-over-year. AFFO guidance was raised, leverage hit a decade low, and the acquisition pipeline remains robust, with significant investments in senior housing and U.K. care homes.
-
Q2 results exceeded expectations with FAD at $0.68/share and improved leverage. AFFO guidance was raised, supported by robust investment activity, stable rent collections, and a strong balance sheet. Industry fundamentals and occupancy continue to recover.